FDA's Taha Kass-Hout and David Litwack speak to The Gray Sheet about the agency's plans to launch a beta version of PrecisionFDA that would allow stakeholders to share their knowledge on next-generation sequencing tests and help to advance the science of validating such tests for a spectrum of diseases. Click here for the full article: http://www.thegraysheet.com/a/01150810017
